Method for Detecting FLT3-ITD Mutation based on Next Generation Sequencing

A next-generation sequencing method using multiple software tools and a FLT3-ITD Score to filter and group FLT3-ITD variants addresses sensitivity and accuracy issues in AML detection, enhancing MRD detection.

KR103043530B1Active Publication Date: 2026-11-06NGENEBIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020250135199
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2024-09-20
Filing Date
2025-09-19
Publication Date
2026-11-06
Estimated Expiration
2045-09-19

AI Technical Summary

Technical Problem

Current methods for detecting FLT3-ITD variants in acute myeloid leukemia (AML) suffer from low sensitivity and inability to accurately measure mutation lengths and sequences, particularly in minimal residual disease (MRD) detection, and existing NGS-based software has limitations in detecting ITD variants and allele frequencies.

Method used

A next-generation sequencing-based method involving multiple variant analysis software to obtain FLT3-ITD variant information, calculate the FLT3-ITD Score (S), and filter and group variants to identify independent FLT3-ITD variants with high sensitivity and accuracy.

Benefits of technology

The method achieves high sensitivity and accuracy in detecting FLT3-ITD variants, reducing false positives and improving MRD detection by utilizing variant location, number, and length information.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112025107594928-PAT00010_ABST
    Figure 112025107594928-PAT00010_ABST
Patent Text Reader

Abstract

The present invention relates to a method for detecting FLT3-ITD variants based on next-generation sequencing, and more specifically, to a method for obtaining sequence information from a biological sample, obtaining primary FLT3-ITD variant information using two or more variant analysis software, calculating a FLT3-ITD Score (SI) from the obtained variant information, and detecting FLT3-ITD variants based thereon. The next-generation sequencing-based FLT3-ITD variant detection method according to the present invention is useful for commercial applications because it significantly reduces the number of detected FLT3-ITD variants by utilizing variant location information, number information, length information, etc., based on primary variant information, thereby having high accuracy and sensitivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for detecting FLT3-ITD variants based on next-generation sequencing analysis, and more specifically, involves obtaining sequence information from a biological sample, obtaining primary FLT3-ITD variant information using two or more variant analysis software, and from the obtained variant information, the FLT3-ITD Score (S I This relates to a method for calculating ) and then detecting FLT3-ITD variants based on this. Background Technology

[0003] More than 90% of leukemia cases are diagnosed in adults aged 20 or older, and the most common types among them are chronic lymphocytic leukemia (35%) and acute myeloid leukemia (AML) (32%) (Cancer Facts & Figures, Atlanta, American Cancer Society; 2014). According to the National Cancer Center's Central Cancer Registry, 20.4% of AML patients are over 70 years old, and 18.4% are in their 60s.

[0004] The revised guidelines for initial diagnostic tests for hematological oncology (In-Suk Kim et al., Lab Med Online 2020; 10(1): 10-24) recommend that gene mutations be performed as a primary diagnostic test for AML, and that the target genes be FLT3-ITD, NPM1, CEBPA, RUNX1, and KIT. Additionally, for secondary testing, it recommends testing for mutations in FLT3-TKD, NRAS, TP53, ABL1 kinase mutation, DNMT3A, IDH1, IDH2, TET2, MLL-PTD, ASXL1, ETV6, EZH2, CBL, and JAK2 genes, and recommends testing using an NGS panel.

[0005] In acute myeloid leukemia (AML), testing for genetic mutations is used not only for diagnosis but also as an indicator to predict prognosis, such as detecting minimal residual disease (MRD), the presence of relapse, and survival rates. Among these, FLT3 (fims-like tyrosine kinase-3) mutations are the most common mutations in AML, and it has been reported that the presence of FLT3 internal tandem duplication (FLT3-ITD) at diagnosis leads to a poor prognosis and affects relapse rates and survival rates. Furthermore, it results in the activation of tyrosine kinases. In addition, the length of ITD of FLT3 varies greatly, and it has been reported that the longer the length, the more severe the symptoms and the poorer the prognosis (Kayser S et al., Blood. 2009 Sep 17;114(12):2386-92; Liu SB, et al., Haematologica. 2019 Jan;104(1):e9-e12).

[0006] Early detection of FLT3-ITD mutations relied on PCR and electrophoresis to identify portions of mutations in the ITD and TKD regions based on length differences; however, this method suffered from very low sensitivity (10%) and the inability to accurately measure mutation lengths and sequences. To overcome this, Fragment Analysis (FA), which quantitatively analyzes amplified products after PCR, was developed (Korean Patent No. 10-2041001; LeukoStrat CDx FLT3 Mutation assay, Invivoscribe). While Fragment Analysis offers improved sensitivity to approximately 3% compared to the PCR method and has the advantage of being able to measure ITD length and ITD burden (ratio), it still cannot perform sequence analysis and lacks the sensitivity required for MRD detection (minimum 10 -4It has the disadvantage of not achieving the level of ). To overcome this drawback, Invivoscribe developed an AML-FLT3 ITD MRD Assay service using NGS, but the sensitivity is 5x10 -5 It is at a certain level, and has the disadvantage of not being able to simultaneously detect mutations in the TKD region, which is important for MRD detection.

[0007] In addition, various analysis software for FLT3-ITD detection using NGS is known, but it has various disadvantages.

[0008] For example, GATK-Mutect2 (https: / / github.com / broadinstitute / gatk / blob / master / src / main / java / org / broadinstitute / hellbender / tools / walkers / mutect / Mutect2.java) has the disadvantage of being unsuitable for detecting ITD variants in MRD-level samples because it cannot detect INDELs longer than 100 bp and cannot identify allele frequencies below a certain level due to their removal via a built-in filter; pindel (https: / / github.com / genome / pindel) has a high true-positive variant detection rate but has the disadvantage of a very high frequency of false-positive variant detection based on an algorithm that utilizes patterns in sequence analysis data; and getITD (https: / / github.com / tjblaette / getitd) has a low false-positive variant detection rate but not only cannot verify the entire sequence based on the ITD variant length but also cannot detect ITD variants longer than a certain length There are drawbacks, and in the case of FLT3_ITD_ext (https: / / github.com / ht50 / FLT3_ITD_ext), although there are few false positive variants, there is a disadvantage that additional analysis work is required because the number of variants called is still large.

[0009] Against this technical background, the inventors have made diligent efforts to develop a next-generation sequencing-based FLT3-ITD variant detection method. As a result, sequence information is obtained from a biological sample, primary FLT3-ITD variant information is obtained using two or more variant analysis software, and from the obtained variant information, the FLT3-ITD Score (S I After calculating ) and detecting FLT3-ITD variants based on this, it was confirmed that FLT3-ITD variants can be detected with high sensitivity and accuracy, and the present invention was completed.

[0010] delete Prior art literature

[65535] Republic of Korea Patent No. 10-2041001 Cancer Facts & Figures, Atlanta, American Cancer Society; 2014In-Suk Kim et al., Lab Med Online 2020; 10(1): 10-24 Kayser S et a., Blood. 2009 Sep 17;114(12):2386-92Liu SB, et al., Haematologica. 2019 Jan;104(1):e9-e12 The problem to be solved

[0011] The objective of the present invention is to provide a method for detecting FLT3-ITD variants based on next-generation sequencing analysis.

[0012] Another objective of the present invention is to provide a device and a computer-readable storage medium used in the above method. means of solving the problem

[0014] To achieve the above objective, the present invention comprises the steps of: (a) extracting nucleic acids from a biological sample to obtain sequence information (reads); (b) aligning the sequence information to a standard chromosome sequence database (reference genome database); (c) obtaining primary FLT3-ITD variant information from the aligned sequence information using two or more variant analysis software; and (d) obtaining the FLT3-ITD Score (S) from the obtained primary FLT3-ITD variant information. I Step of calculating ); (e) calculated S I A method for detecting FLT3-ITD variants is provided, comprising: (f) removing variant information when the value is less than a threshold value; (g) grouping each of the FLT3-ITD variant information that was not removed; (g) distinguishing between independent variants and dependent variants in the grouped FLT3-ITD variant information; and (h) determining independent variants as FLT3-ITD variants.

[0015] The present invention also comprises: a decoding unit for decoding sequence information from a biological sample; an alignment unit for aligning the decoded sequence information to a standard chromosome sequence database; a variant information obtaining unit for obtaining primary variant information from the aligned sequence information using two or more variant analysis software; a calculation unit for calculating the FLT3-ITD Score from the obtained primary variant information; and the calculated S I A FLT3-ITD variant detection device is provided, comprising: a filter unit that filters variant information based on a value; a variant classification unit that groups unremoved variant information and distinguishes between independent variants and dependent variants; a variant detection unit that determines variants classified as independent variants as FLT-ITD variants; and an integration unit that integrates FLT-ITD variants detected by two or more variant analysis software.

[0016] The present invention also comprises a computer-readable storage medium, the instruction configured to be executed by a processor for detecting FLT3-ITD variants in sequence information, the instruction comprising: (a) extracting nucleic acids from a biological sample to obtain sequence information (reads); (b) aligning the sequence information to a reference genome database; (c) obtaining primary FLT3-ITD variant information from the aligned sequence information using two or more variant analysis software; and (d) obtaining a FLT3-ITD Score (S) from the obtained primary FLT3-ITD variant information. I Step of calculating ); (e) calculated S I A computer-readable storage medium is provided that includes instructions configured to be executed by a processor that performs FLT3-ITD variant detection in sequence information, through a method characterized by further including: (f) removing variant information when the value is less than a reference value; (g) grouping each of the FLT3-ITD variant information that was not removed; (h) distinguishing independent variants and dependent variants in the grouped FLT3-ITD variant information; (h) determining independent variants as FLT3-ITD variants; and (i) integrating FLT-ITD variants detected by two or more variant analysis software based on variant location and sequence. Effects of the invention

[0018] The next-generation sequencing-based FLT3-ITD variant detection method according to the present invention utilizes variant location information, number information, length information, etc., based on primary variant information to drastically reduce the number of detected FLT3-ITD variants, and thus has high accuracy and sensitivity, making it useful for commercial applications. Brief explanation of the drawing

[0020] Figure 1a is an overall flowchart of the next-generation sequencing-based FLT3-ITD mutation detection method of the present invention, and Figure 1b is a detailed flowchart of the mutation evaluation step. FIG. 2 is an example of primary mutation information obtained according to an embodiment of the present invention, wherein the upper red box represents an actual ITD mutation, the middle orange box represents a mutation caused by an error in the mutation detection software, the yellow box represents a simple insertion mutation that is not an ITD, and any mutation without a box represents a mutation caused by an error that occurred during the step of obtaining sequence information (reads) from a biological sample. FIG. 3 is an example of a method for correcting the position of a mutation of primary mutation information obtained according to one embodiment of the present invention. FIG. 4 shows an example in which the variation position of primary variation information obtained according to one embodiment of the present invention is actually corrected. FIG. 5 is a conceptual diagram illustrating the process of filtering grouped variation information obtained according to one embodiment of the present invention and separating it into independent variation and dependent variation. FIG. 6 shows a mutation detection method constructed according to an embodiment of the present invention and the number of mutations (RAW) of primary mutation information, S I This is a graph showing the number of variations with only the variable values ​​for calculation filtered (BASIC) and the number of variations obtained from the final result (FINAL). Specific details for implementing the invention

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein and the experimental methods described below are well known and commonly used in the art.

[0022] Terms such as first, second, A, B, etc., may be used to describe various components, but such components are not limited by the said terms and are used solely for the purpose of distinguishing one component from another. For example, without departing from the scope of rights of the technology described below, the first component may be named the second component, and similarly, the second component may be named the first component. The term "and / or" includes a combination of multiple related described items or any of the multiple related described items.

[0023] In terms used in this specification, singular expressions should be understood to include plural expressions unless the context clearly indicates otherwise, and terms such as “includes” should be understood to mean that the described features, number, step, action, component, part, or combination thereof exist, and not to exclude the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0024] Before providing a detailed description of the drawings, it is to clarify that the classification of components in this specification is merely based on the primary function each component is responsible for. That is, two or more components described below may be combined into a single component, or a single component may be divided into two or more components based on more subdivided functions. Furthermore, each component described below may additionally perform some or all of the functions of other components in addition to its own primary function, and it goes without saying that some of the primary functions of each component may be exclusively performed by other components.

[0025] Furthermore, in performing the method or operation method, each process constituting the method may occur differently from the specified order unless a specific order is clearly indicated in the context. That is, each process may occur in the same order as specified, may be performed substantially simultaneously, or may be performed in the reverse order.

[0027] In the present invention, sequence information is obtained from a biological sample, primary FLT3-ITD variant information is obtained using two or more variant analysis software, and the FLT3-ITD Score (S I We intended to confirm that FLT3-ITD variants can be detected with high sensitivity and accuracy by calculating ) and then detecting FLT3-ITD variants based on this.

[0029] That is, in one embodiment of the present invention, primary variant information is obtained from NGS data obtained from a biological sample using two or more ITD callers, and then the FLT3-ITD Score (S) reflecting the number of allele observations, depth, frequency, length, and degree of agreement with a standard reference sequence in the variant information is obtained. I It was confirmed that the performance is excellent when ) is calculated, filtering is performed based on it, and then the unremoved variant information is grouped to detect only independent variants (Fig. 6).

[0030] In the present invention, the term "reads" refers to a single nucleic acid fragment obtained by analyzing sequence information using various methods known in the art. Accordingly, in this specification, the terms "sequence information" and "reads" have the same meaning in that they refer to the result obtained by acquiring sequence information through a sequencing process.

[0031] In the present invention, variant information refers to a read suspected of being a FLT3-ITD variant output from variant analysis software, and examples thereof are as described in FIG. 2, but are not limited thereto.

[0033] Accordingly, in one aspect, the present invention,

[0034] The present invention relates to a method for detecting FLT3-ITD variants comprising the following steps:

[0035] (a) A step of extracting nucleic acids from a biological sample to obtain sequence information (reads);

[0036] (b) A step of aligning sequence information to a standard chromosome sequence database (reference genome database);

[0037] (c) A step of obtaining primary FLT3-ITD variant information from aligned sequence information using two or more variant analysis software programs;

[0038] (d) FLT3-ITD Score(S from the obtained primary FLT3-ITD variant information I Step of calculating );

[0039] (e) Calculated S I A step to remove mutation information when the value is less than the threshold value;

[0040] (f) A step of grouping each unremoved FLT3-ITD variant information;

[0041] (g) a step of distinguishing independent variants and dependent variants in grouped FLT3-ITD variant information; and

[0042] (h) Step of determining the independent variant as a FLT3-ITD variant.

[0044] In the present invention, the method

[0045] (i) It may be characterized by additionally including a step of integrating FLT-ITD variants detected in two or more variant analysis software based on variant location and sequence.

[0047] In the present invention, the above step (a) may be characterized as being performed by a method comprising the following steps:

[0048] (ai) A step of obtaining nucleic acids from a biological sample;

[0049] (a-ii) a step of removing proteins, lipids, and other residues from the collected nucleic acid using a salting-out method, a column chromatography method, or a beads method to obtain purified nucleic acid;

[0050] (a-iii) a step of amplifying a purified nucleic acid or a nucleic acid randomly fragmented by enzymatic cutting, grinding, or a hydroshear method using the primer set of claim 1 or 2, and then producing a single-end sequencing or pair-end sequencing library;

[0051] (a-iv) a step of reacting the produced library with a next-generation sequencer; and

[0052] (av) A step of obtaining sequence information (reads) of nucleic acids from a next-generation gene sequencing machine.

[0053] In the present invention, the biological sample refers to any substance, biological fluid, tissue, or cell obtained from or derived from an individual, for example, whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, blood (including plasma and serum), sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate. It may include, but is not limited to, aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell, cell extract, semen, hair, saliva, urine, oral cells, placental cells, cerebrospinal fluid, and mixtures thereof.

[0054] In the present invention, the step of obtaining sequence information of step (a) may be characterized by obtaining the obtained DNA through targeted deep sequencing at a depth of 1.4 million to 1.6 million reads.

[0056] The term “” in the present invention refers to Next Generation Sequencing, and also refers to next-generation sequencing and next-generation DNA sequencing. This refers to a technology that fragments a whole genome and performs high-throughput sequencing based on chemical reactions (hybridization) of the fragments, or performs high-throughput sequencing by amplifying target gene regions using multiplex PCR. It includes technologies from Agilent, Illumina, Roche, and Life Technologies, and in a broader sense, is defined to include third-generation technologies such as those from Pacificbio and Nanopore Technology, as well as fourth-generation technologies.

[0057] The technology originally referred to as Next Generation Sequencing (NGS) corresponds to the second generation of automation. The term NGS was used to distinguish it from the first automated instruments and to differentiate it from the subsequent Next NGS instruments (also referred to as the next-next generation or third-generation NGS). However, as the competition to develop efficient sequencing technologies accelerates and sequencing techniques are continuously developed based on the introduction of new technologies and the intended use of platforms, the distinction between generations of sequencing technologies has become blurred. Consequently, the term NGS is now used in a broad sense to encompass all sequencing technologies that have emerged since automated Sanger sequencing.

[0058] Technologies introduced in NGS can be broadly classified into three categories: clonal amplification, massively parallel, and new direct-readable sequencing methods (non-Sanger methods) (base / color calling). Clonal amplification eliminates the cloning process by removing the library construction step, while massively parallel methods improve efficiency by handling hundreds of thousands of clones simultaneously. New direct-readable sequencing methods demonstrate the effect of eliminating the capillary electrophoresis process.

[0059] The process of obtaining template clones has been simplified by clonal amplification. Sequencing using the Sanger method requires template DNA approximately 500 base pairs in length. After constructing a BAC library, short fragments must be cloned via subcloning and then amplified in bacteria. The new method eliminates both the cumbersome library construction and cloning processes, allowing template clones to be obtained by directly cutting DNA into appropriately short fragments and amplifying them directly using primers via PCR. Strategies such as bead-based, solid-state, and DNA nanoball generation are used for clonal amplification.

[0060] Emulsion PCR is used for bead-based clonal amplification. In emulsion PCR, a DNA library—an aggregate obtained by fragmenting genomic DNA—is spatially separated into small aqueous droplets within an oil medium. The DNA is then amplified within the emulsion alongside microbeads modified with one PCR primer on their surface. This method allows over one million clonal DNA fragments derived from a single DNA fragment to be immobilized onto a single bead. A representative solid-state method is bridge amplification. In bridge amplification, adapter oligonucleotides are attached to both ends of fragmented DNA. When this is flowed across the surface of a glass flow cell, the DNA randomly binds to primers complementary to the adapters immobilized on the surface. When PCR is performed in this state, the free ends of the immobilized DNA bind to surrounding free primers, forming a bridge structure, and amplification proceeds. When amplification proceeds in this way, a cluster is formed that performs the same role as the aforementioned bead.

[0061] NGS employs a massively parallel method to arrange the aforementioned clones in a plate-like fashion and perform sequencing analysis. Since the number of template clones is very large, preparing them separately is time-consuming. The process of reading the sequence signal from the template also poses a serious limiting factor that reduces efficiency. Processing hundreds of thousands of different clones using a massively parallel method can drastically reduce time.

[0062] To eliminate the cumbersome electrophoresis process, a new method has been developed that departs from the Sanger method, which involves inducing a reaction in a template and then directly reading the sequence information of each template using the resulting signal. The sequencing methods replacing the Sanger method are broadly divided into Sequencing by Ligation (SBL) and Sequencing by Synthesis (SBS).

[0063] The SBL method utilizes the repetitive ligation of DNA fragments, wherein an anchor having n bases binds complementarily to the template DNA, and a probe containing two randomly encoded bases labeled by a fluorescent label followed by degenerate or universal bases is added to a DNA library slide precipitated with the aforementioned beads or clusters. A probe having two encoded sequences complementary to the template DNA fragment immediately following the anchor is ligated to the anchor, and the two encoded base sequences are analyzed through fluorescent label imaging of the slide. Once the two sequences are analyzed, the degenerate base sequence and fluorescent particles are removed, and the above process of adding probes is repeated. In addition to the aforementioned n anchor, this method analyzes the sequence of the entire template DNA fragment by using anchors having n+2 and n+4 bases and analyzing them repeatedly.

[0064] SBS is further divided into Cyclic Reversible Termination (CRT) and Single Nucleotide Addition (SNA).

[0065] The CRT method utilizes a process similar to the automated Sanger method, in which a mixture of primers, DNA polymerase, and modified nucleotides is added to a slide containing DNA clusters amplified using a solid-state method. The modified nucleotides are blocked with 3'-O-azidomethyl to prevent further polymerization and labeled with base-specific, subsequently removable fluorescent labels. After polymerization, unpolymerized bases are washed away, and bases are identified through imaging using a Total Internal Reflection Fluorescence (TIRF) microscope. Once bases are identified, the fluorescent labels are degraded, and the 3'-OH is regenerated using the reducing agent Tris-2-Carboxyethyl)phosphine (TCEP). This process is repeated to analyze the sequence of template DNA without electrophoresis.

[0066] SNA is a method that analyzes base sequences by converting ions generated when DNA polymerase binds single nucleotides into light. The SNA method is represented by the pyrosequencing method used in Roche’s 454 instrument, which reads the pyrophosphate released when nucleotides bind using light. By sequentially adding four types of dNTPs (A, G, T, C), reacting them, and repeating the washing process, light is emitted whenever a polymerization reaction occurs, thereby determining the base sequence.

[0067] Representative analytical instruments using SBL include the SOLiD series from the former Life Technologies, and representative analytical instruments using SBS include Illumina's Hiseq and MiSeq series (CRT method) and Roche's 454 series (SNA method).

[0069] In the present invention, the sequence information obtained after performing the alignment step of step (b) may be in the bam file format, but is not limited thereto, and the standard reference chromosome sequence database may be a reference chromosome registered with a public health institution such as NCBI.

[0071] In the present invention, the variant analysis software of step (c) can be used without limitation as long as it is software capable of detecting FLT3-ITD variants, and preferably, it may be characterized as being two or more selected from the group consisting of GATK-Mutect2, pindel. GetITD, FLT3_ITD_ext, ScanITD and ITDetect, but is not limited thereto.

[0072] In the present invention, as preferred examples, pindel (https: / / github.com / genome / pindel) and FLT3_ITD_ext (https: / / github.com / ht50 / FLT3_ITD_ext) were used.

[0074] In the present invention, the FLT3-ITD Score(S of step (d) above is I ) can be characterized by being calculated using the following Formula 1:

[0075] Formula 1: S I =S α x S β x S γ x S f x S m

[0076] Here, S α is a value calculated based on the number of alleles observed in the variant information (allele observation count, AO), and

[0077] S β is a value calculated based on the allele depth (DP) in the variant information, and

[0078] S γis a value calculated based on the allele frequency (AF) from the variant information, and

[0079] S f is a value calculated based on the allele length from the variant information, and

[0080] S m is a value calculated based on the allele length and the number of bases that match the allele and the standard reference sequence in the variant information.

[0082] In the present invention, the above S I The value may be characterized as being between 0 and 1.

[0084] In the present invention, the above S α is the number of alleles observed in the variant information (allele observation count, AO) as the count reference value (C α It can be characterized as a value between 0 and 1 calculated by dividing by ).

[0085] In the present invention, the number reference value (C α ) may be characterized as being 3 to 7, more preferably 4 to 6, and most preferably 5, but is not limited thereto.

[0087] In the present invention, the above S β In the variant information, the allele depth (DP) is the depth reference value (C β Characterized by being 1 if greater than or equal to ) and 0 if less than the depth reference value

[0088] In the present invention, the depth reference value (C β ) may be characterized as being 1000 to 100000, more preferably 5000 to 50000, most preferably 10000, but is not limited thereto.

[0090] In the present invention, the above S γis the frequency reference value (C) for the allele frequency (AF) in the variant information. γ It can be characterized as a value between 0 and 1, calculated by dividing by ).

[0091] In the present invention, the frequency reference value (C γ ) may be characterized as being 0.00001 to 0.0001, more preferably 0.00003 to 0.0007, most preferably 0.00005, but is not limited thereto.

[0093] In the present invention, the above S f The allele length in the variant information may be characterized as being 1 when it is a multiple of 3, and having an ε value of 0 or greater and less than 1 when it is not a multiple of 3, wherein the ε value may be 0.5 to 0.9, more preferably 0.6 to 0.85, and most preferably 0.8, but is not limited thereto.

[0095] In the present invention, S m It is characterized by calculating the number of bases matching the standard reference sequence in the variant information by dividing it by the length of the allele, and can be characterized as being 0 or greater and 1 or less.

[0096] In the present invention, the number of allowable mismatches according to the length of the allele may be characterized as 0 when the length of the allele is 0 or more and 10 or less, 5 when the length of the allele is 10 or more and 50 or less, 10 when the length of the allele is greater than 50 and 100 or less, and 10 when the length of the allele is greater than 100 and 0.1.

[0097] In the present invention, additional comparisons are performed at 1 bp intervals with the preceding and succeeding standard reference sequences having the same length as the length of the allele in the standard reference sequence, S mIt may be characterized by additionally including a step of modifying the location with the largest value to the new mutation location of the mutation information.

[0099] In the present invention, the reference value of step (e) may be characterized as being 0.3 to 0.9, more preferably 0.4 to 0.8, and most preferably 0.7, but is not limited thereto.

[0101] In the present invention, the step (f) may be performed by a method including a step of determining one group when the location of a variant extracted from variant information overlaps with one or more other variant information.

[0103] In the present invention, the step of distinguishing between independent variation and dependent variation in step (g) may be characterized by being performed by a method including the following steps:

[0104] (gi) A step of determining as an independent variant if the sequence agreement between variant information within a group is 80% or less;

[0105] (g-ii) A step of determining as an independent variant if the sequence concordance is greater than 80% but the proportion of overlapping sequences is 70% or less;

[0106] (g-iii) Although the sequence concordance is greater than 80%, the variant allele frequency (VAF) and S of the variant information I A step of determining as independent variants if values ​​are 90% or more similar;

[0107] (g-iv) A step of determining variant information that was not determined as an independent variant in the above step as a dependent variant; and

[0108] (gv) A step of adding the number of alleles (AO) of the dependent variant to the independent variant with the highest sequence agreement and correcting VAF.

[0110] In another aspect, the present invention,

[0111] A decoding unit that decodes sequence information from a biological sample;

[0112] Alignment unit that aligns decoded sequence information to a standard chromosome sequence database;

[0113] A variant information obtaining unit that obtains primary variant information from aligned sequence information using two or more variant analysis software;

[0114] A calculation unit that calculates the FLT3-ITD Score from the obtained primary mutation information;

[0115] Calculated S I A filter unit that filters mutation information based on values;

[0116] A variation classification unit that groups unremoved variation information and distinguishes between independent and dependent variations;

[0117] A variant detection unit that determines a variant classified as an independent variant as a FLT-ITD variant; and

[0118] An integration unit that integrates FLT-ITD variants detected by two or more variant analysis software;

[0119] This relates to a FLT3-ITD variant detection device including

[0120] In the present invention, the decoding unit may include a nucleic acid injection unit that injects nucleic acid extracted from an independent device; and a sequence information analysis unit that analyzes sequence information of the injected nucleic acid, and preferably may be an NGS analysis device, but is not limited thereto.

[0121] In the present invention, the alignment unit may be characterized by receiving sequence information data generated from an independent device and aligning it.

[0123] In another aspect, the present invention,

[0124] A computer-readable storage medium comprising instructions configured to be executed by a processor for detecting FLT3-ITD variants in sequence information,

[0125] (a) A step of extracting nucleic acids from a biological sample to obtain sequence information (reads);

[0126] (b) A step of aligning sequence information to a standard chromosome sequence database (reference genome database);

[0127] (c) A step of obtaining primary FLT3-ITD variant information from aligned sequence information using two or more variant analysis software programs;

[0128] (d) FLT3-ITD Score(S from the obtained primary FLT3-ITD variant information I Step of calculating );

[0129] (e) Calculated S I A step to remove mutation information when the value is less than the threshold value;

[0130] (f) A step of grouping each unremoved FLT3-ITD variant information;

[0131] (g) A step of distinguishing independent variants and dependent variants in grouped FLT3-ITD variant information;

[0132] (h) a step of determining an independent variant as a FLT3-ITD variant; and

[0133] (i) A method characterized by additionally including the step of integrating FLT-ITD variants detected by two or more variant analysis software based on variant location and sequence.

[0134] The present invention relates to a computer-readable storage medium comprising instructions configured to be executed by a processor that performs FLT3-ITD variant detection in sequence information.

[0136] In other embodiments, the method according to the present invention may be implemented using a computer. In one embodiment, the computer includes one or more processors connected to a chipset. Additionally, memory, a storage device, a keyboard, a graphics adapter, a pointing device, and a network adapter are connected to the chipset. In one embodiment, the performance of the chipset is enabled by a memory controller hub and an I / O controller hub. In another embodiment, the memory may be used by being directly connected to the processor instead of the chipset. The storage device is any device capable of holding data, including a hard drive, a CD-ROM (Compact Disk Read-Only Memory), a DVD, or other memory device. The memory is involved in data and instructions used by the processor. The pointing device may be a mouse, a trackball, or other type of pointing device and is used to transmit input data to the computer system in combination with a keyboard. The graphics adapter displays images and other information on a display. The network adapter is connected to the computer system via a local or long-distance network. However, the computer used in this invention is not limited to the above configuration and may lack some configuration or include additional configuration, and may also be part of a Storage Area Network (SAN), and the computer of this invention may be configured to be suitable for the execution of a module in a program for performing the method according to this invention.

[0138] In this invention, the term "module" may refer to a functional and structural combination of hardware for carrying out the technical concept according to this invention and software for driving said hardware. For example, said module may refer to a logical unit of a specific code and a hardware resource for executing said code, and it is obvious to those skilled in the art that it does not necessarily refer to physically connected code or to a single type of hardware.

[0140] Examples

[0141] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0143] Example 1. DNA was extracted from a sample, and next-generation sequencing was performed.

[0144] Remaining specimens meeting the requirements for a consent waiver were obtained and used from samples remaining after testing for FLT3-ITD at a clinical institution (Department of Laboratory Medicine, Seoul St. Mary's Hospital) (IRB No._KC23DSST0045). The specimens consisted of DNA extracted using the QIAamp DSP DNA Blood Mini Kit or the QIAsymphony Dsp DNA Mini Kit (QIAGEN NV, Germany) from bone marrow collected from 15 healthy individuals (FLT3-ITD negative) and 43 FLT3-ITD positive patients (41 specimens diagnosed as FLT3-ITD positive at initial examination and 135 specimens monitored for FLT3-ITD after treatment). MRDaccuPanel TM A library was prepared using AML FLT3, and sequencing was performed at 149 x 149 cycles using MiSeq Dx or NextSeq Dx (Illumina, USA).

[0145] As a result, it was confirmed that an average of 26,000 leads were generated for specimens that tested positive at the initial examination, and an average of 1.5 million leads for other specimens (FLT3-ITD negative specimens and specimens under follow-up after treatment).

[0146] The composition of the sample is as shown in Table 1 below.

[0147] classification Number of samples Number of patients Initial FLT3-ITD negative 15 pieces 15 people Initial FLT3-ITD positive 41 pieces 43 people Post-treatment FLT3-ITD follow-up 135 pieces Total 191 58 people

[0149] Example 2. Obtaining primary mutation information and S I Value calculation

[0150] 2-1. Obtaining Primary Mutation Information

[0151] ITD variants were extracted from the BAM file of the sample obtained and aligned in Example 1 using the tools pindel and FLT3_ITD_ext. Pindel is an algorithm that finds and analyzes insertions / deletions using a sequence pattern growth algorithm based on the sequence information of reads, and FLT3_ITD_ext collects sequences among the aligned reads that have patterns different from the standard nucleotide sequence and determines whether the sequence is repeated, thereby generating a candidate group of ITD variants in the form of variant call format (VCF). At this time, variants with a length of less than 6 generated by the two tools were excluded.

[0152] 2-2. S I Variable calculation for value calculation

[0153] After obtaining STATs for each variant information as shown in Table 2 below from the primary variant information obtained in Example 2-1, S is obtained by applying the judgment criteria value α , S β , and S γ The variable was calculated.

[0154] The judgment criteria used were C = 5, C = 10000, and C = 0.00005.

[0155] Variant Stat Cutoff Stat score Allele Observation Count (AO) C S = / C( 0 ≤ S ≤ 1 ) Allele Depth (DP) C S = 1, ( ≥ C)S = 0, ( < C) Allele Frequency (AF) C S = / C( 0 ≤ S ≤ 1 )

[0156] Table 3 below shows the status of the obtained FLT3-ITD primary mutation information, and Table 4 shows some of the calculated score values.

[0157]

[0158] In Table 3 above, ALT refers to the read length of the variant detected in the primary variant information.

[0159]

[0160] S f The value is used to determine whether the obtained variant information is actual ITD variant information, considering that general ITD variants are in the form of in-frame insertions.

[0161] If the length of the allele sequence is a multiple of 3, it is determined to be 1, and otherwise, it is determined to be an ε value greater than or equal to 0 and less than 1, for example, 0.8 was used. This can be expressed as a formula as Equation 2.

[0162] Formula 2:

[0163] Here, L represents the length of the allele sequence.

[0164] That is, S in Table 4 above f The values ​​were determined as 0.8, 0.8, 0.8, 1, and 1, respectively.

[0165] The Sm value is a value used to correct the consistency of the variant information obtained based on the fact that the allele sequence of the ITD variant is a repeat of the standard reference sequence at the genomic location where the variant appears, and it was calculated by dividing the number of bases in the obtained variant information that match the standard reference sequence by the length of the allele.

[0166] This can be expressed as a formula, as in Formula 3.

[0167] Formula 3:

[0168] Here, m represents the number of bases in the obtained variant information that match the standard reference sequence, and L represents the length of the allele sequence.

[0169] In addition, as shown in Table 5, a limit value for the maximum allowable mismatch is set according to the length of the allele sequence, and if this is exceeded, S m The value was determined to be 0.

[0170] ITD length Maximum allowable mismatch note 0 ≤ ≤ 10 0 If the maximum allowed mismatch is exceeded, S = 0 0 ≤ ≤ 50 5 0 ≤ ≤ 100 10 > 100 * 0.1

[0171] In addition, as described in Fig. 3, to correct errors in the primary variant information, at the location where the ITD appears, a comparison with the preceding and succeeding standard reference sequences is performed at 1 bp intervals for a length equal to the length of the ITD sequence, S m The location with the largest value was modified to the new mutation location of the mutation information.

[0172] That is, when the primary mutation information was determined to be at the 28608257th position of the 13th chromosome as shown in Table 6 below, sequence comparisons were performed in 1 bp increments as described in Figure 4, and the mutation location and information were modified to the 28608253rd position of the 13th chromosome, which is the position with the largest Sm value, as shown in Table 7.

[0173]

[0174]

[0175] 2-3. S I Value calculation

[0176] S I The value was calculated using Formula 1 below.

[0177] Formula 1: S I =S α x S β x S γ x S f x S m

[0179] Example 3. S I Value-based filtering and mutation integration

[0180] 3-1. Filtering

[0181] S calculated from each primary mutation information I If the value was 0, it was determined to be a simple insertion rather than an ITD mutation and removed, and S I All variant information with a value less than 0.7 was also removed.

[0182] 3-2. Variant Integration

[0183] Each variant information that was not removed in 3-1 was grouped according to the position and length of the variant.

[0184] Independent and dependent variants were distinguished by comparing the ITD sequences of variants within the group; first, a representative variant was selected. The representative variant was selected based on the variant having the maximum within-group VAF value, and if the allele sequence agreement with the selected representative variant is 80% or less, if the sequence agreement is greater than 80% but the proportion of overlapping sequences is 70% or less, or if the sequence agreement is greater than 80% but the variant information's allele frequency (VAF) and S I If the values ​​were more than 90% similar, they were determined to be independent variants, and the remaining variant information was classified as dependent variants.

[0185] Subsequently, each dependent variant and independent variant were compared; the number of alleles (AO) of the dependent variant was added to the independent variant with the highest sequence agreement, and the VAF of the independent variant was corrected to determine the final FLT3-ITD variant.

[0186] That is, as described in Figure 5 and Table 8, V1 to V3 were removed below the reference value, V4 and V7 had the lowest sequence concordance within the group, and S IV5, V6, V8, and V9 were determined to be independent variants due to their high values ​​and VAFs, and when V5, V6, V8, and V9 were compared with the sequences of V4 and V7, respectively, V5 was determined to be a dependent variant of V4 as it had the highest sequence agreement with V4, and the others were determined to be dependent variants of V7 through the same process, after which the respective AO values ​​were added to the independent variants and the VAFs were modified.

[0187]

[0188] Subsequently, the independent variant information obtained from each tool was organized to remove duplicates and integrated into a single dataset.

[0189] That is, as indicated in Table 9, if the independent variant information of FLT3_ITD_ext and the independent variant information of pindel partially match, they are integrated in the form shown in Table 10.

[0190]

[0191]

[0193] Example 4. Verification of the performance of the constructed mutation detection method

[0194] Based on the data obtained in Example 1, the results of performing up to the method of Example 2 and up to the method of Example 3 were compared, and as shown in Fig. 6, it was confirmed that the number of FLT3-ITD variants detected as a result of performing up to Example 3 was significantly reduced.

[0195] In addition, true positive mutations were identified. The initial sample was subjected to FA testing and the methods up to Example 3, while the follow-up sample was subjected to mutation detection using the methods up to Example 3. As a result, mutations were detected with an accuracy of 100% in the initial sample and over 95% in the follow-up sample, and it was confirmed that the mutations not detected in the follow-up sample were mutations of less than 0.001%, which is the minimum detection limit.

[0197] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

Claim 1 A method for detecting FLT3-ITD variants comprising the following steps: (a) extracting nucleic acids from a biological sample to obtain sequence information (reads); (b) aligning the sequence information to a reference genome database; (c) obtaining primary FLT3-ITD variant information from the aligned sequence information using two or more variant analysis software; (d) FLT3-ITD Score (S I Step to calculate ) using Formula 1 below: Formula 1: S I =S α x S β x S γ x S f x S m Here, S α is a value calculated based on the number of alleles observed in the variant information (allele observation count, AO), and S β is a value calculated based on the allele depth (DP) in the variant information, and S γ is a value calculated based on the allele frequency (AF) in the variant information, and S f is a value calculated based on the allele length from the variant information, and S m is a value calculated based on the allele length in the variant information and the number of bases matching the allele and the standard reference sequence; (e) calculated S I (f) a step of removing variant information when the value is less than a threshold value; (g) a step of grouping each of the unremoved FLT3-ITD variant information; (g) a step of distinguishing between independent variants and dependent variants in the grouped FLT3-ITD variant information; and (h) a step of determining independent variants as FLT3-ITD variants. Claim 2 A detection method according to claim 1, wherein step (a) is performed by a method comprising the following steps: (ai) obtaining nucleic acid from a biological sample; (a-ii) removing proteins, lipids, and other residues from the collected nucleic acid using a salting-out method, a column chromatography method, or a bead method to obtain purified nucleic acid; (a-iii) amplifying the purified nucleic acid or nucleic acid randomly fragmented by enzymatic cutting, grinding, or a hydroshear method, and then constructing a single-end sequencing or pair-end sequencing library; (a-iv) reacting the constructed library with a next-generation sequencer; and (av) obtaining sequence information (reads) of nucleic acid from the next-generation sequencer. Claim 3 A method according to claim 1, wherein the variant analysis software of step (c) is two or more selected from the group consisting of GATK-Mutect2, pindel. GetITD, FLT3_ITD_ext, ScanITD, and ITDetect. Claim 4 delete Claim 5 In paragraph 1, the above S I A method characterized by the value being 0 or greater and 1 or less. Claim 6 In paragraph 1, the above S α is the number of alleles observed in the variant information (allele observation count, AO) as the count reference value (C α A method characterized by a value of 0 or greater and 1 or less, calculated by dividing by ). Claim 7 In Clause 6, the above number standard value (C α A method characterized by ) being 3 to 7. Claim 8 In paragraph 1, the above S β In the variant information, the allele depth (DP) is the depth reference value (C β A method characterized by being 1 if greater than ) and 0 if less than the depth reference value. Claim 9 In paragraph 8, the depth reference value (C β A method characterized by ) being 1000 to 100000. Claim 10 In paragraph 1, the above S γ is the frequency reference value (C) for the allele frequency (AF) in the variant information. γ A method characterized by a value of 0 or greater and 1 or less, calculated by dividing by ). Claim 11 In Clause 10, the above frequency reference value (C γ A method characterized in that ) is 0.00001 to 0.0001. Claim 12 In paragraph 1, the above S f A method characterized by having an ε value of 1 if the allele length in the variant information is a multiple of 3, and an ε value of 0 or greater and less than 1 if it is not a multiple of 3. Claim 13 A method according to claim 12, characterized in that the ε value is 0.5 to 0.

9. Claim 14 In paragraph 1, S m A method characterized by calculating the number of bases matching a standard reference sequence in variant information by dividing it by the length of the allele, and being 0 or greater and 1 or less. Claim 15 In Clause 14, the above S m A method characterized by additionally including a step of determining 0 if the number of acceptable mismatches exceeds the allele length. Claim 16 A method according to claim 15, characterized in that the number of permissible mismatches according to the length of the allele is 0 when the allele length is 0 or more and 10 or less, 5 when the allele length is 10 or more and 50 or less, 10 when the allele length is greater than 50 and 100 or less, and 10 when the allele length is greater than 100, and is the allele length * 0.

1. Claim 17 In paragraph 14, by performing additional comparisons of 1 bp each with the preceding and succeeding standard reference sequences of the same length as the length of the said allele in the standard reference sequence, S m A method characterized by additionally including a step of modifying the location with the largest value to a new variant location of the variant information. Claim 18 A method according to claim 1, characterized in that the reference value of step (e) is 0.3 to 0.

9. Claim 19 A method according to claim 1, wherein the above step (f) is performed by including a step of determining one group when the location of a variant extracted from variant information overlaps with one or more other variant information. Claim 20 A method according to claim 1, characterized in that the step of distinguishing between independent variants and dependent variants in step (g) is performed by a method comprising the following steps: (gi) a step of determining an independent variant when the sequence similarity between variant information within a group is 80% or less; (g-ii) a step of determining an independent variant when the sequence similarity is greater than 80% but the ratio of overlapping sequences is 70% or less; (g-iii) a step in which the sequence similarity is greater than 80% but the variant allele frequency (VAF) and S of the variant information I A step of determining an independent variant when the values ​​are each 90% or more similar; (g-iv) a step of determining variant information not determined as an independent variant in the above step as a dependent variant; and (gv) a step of adding the number of alleles (AO) of the dependent variant to the independent variant with the highest sequence agreement and correcting the VAF. Claim 21 A method according to claim 1, further comprising the step of (i) integrating FLT-ITD variants detected by two or more variant analysis software based on variant location and sequence. Claim 22 A decoding unit for decoding sequence information from a biological sample; an alignment unit for aligning the decoded sequence information with a standard chromosome sequence database; a variant information acquisition unit for obtaining primary variant information from the aligned sequence information using two or more variant analysis software programs; and a calculation unit for calculating the FLT3-ITD Score from the obtained primary variant information using the following Formula 1: Formula 1: S I =S α x S β x S γ x S f x S m Here, S α is a value calculated based on the number of alleles observed in the variant information (allele observation count, AO), and S β is a value calculated based on the allele depth (DP) in the variant information, and S γ is a value calculated based on the allele frequency (AF) in the variant information, and S f is a value calculated based on the allele length from the variant information, and S m is a value calculated based on the allele length in the variant information and the number of bases matching the allele with the standard reference sequence; the calculated S I A FLT3-ITD variant detection device comprising: a filter unit for filtering variant information based on values; a variant classification unit for grouping unremoved variant information and distinguishing between independent variants and dependent variants; a variant detection unit for determining variants classified as independent variants as FLT-ITD variants; and an integration unit for integrating FLT-ITD variants detected by two or more variant analysis software. Claim 23 A computer-readable storage medium comprising instructions configured to be executed by a processor for detecting FLT3-ITD variants in sequence information, wherein the instructions include: (a) a step of extracting nucleic acids from a biological sample to obtain sequence information (reads); (b) a step of aligning the sequence information to a standard chromosome sequence database (reference genome database); (c) a step of obtaining primary FLT3-ITD variant information from the aligned sequence information using two or more variant analysis software; and (d) a FLT3-ITD Score (S I Step to calculate ) using Formula 1 below: Formula 1: S I =S α x S β x S γ x S f x S m Here, S α is a value calculated based on the number of alleles observed in the variant information (allele observation count, AO), and S β is a value calculated based on the allele depth (DP) in the variant information, and S γ is a value calculated based on the allele frequency (AF) in the variant information, and S f is a value calculated based on the allele length from the variant information, and S m is a value calculated based on the allele length in the variant information and the number of bases matching the allele and the standard reference sequence; (e) calculated S I A computer-readable storage medium comprising instructions configured to be executed by a processor performing FLT3-ITD variant detection in sequence information, through a method characterized by further including: (f) removing variant information when the value is less than a reference value; (g) grouping each FLT3-ITD variant information that was not removed; (h) distinguishing independent variants and dependent variants in the grouped FLT3-ITD variant information; (h) determining independent variants as FLT3-ITD variants; and (i) integrating FLT-ITD variants detected by two or more variant analysis software based on variant location and sequence.